SCHEMBL829490

SCHEMBL829490

Cc1ccc2nc(Cl)cc(Cl)c2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.72
KDM4E B2RXH2 3/20 0.49
MAPT P10636 2/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP3A4 P08684 2/20 0.47
CYP2C19 P33261 2/20 0.47
HIF1A Q16665 1/20 0.47
ELANE P08246 1/20 0.44
ACHE P22303 5/20 0.42
BCHE P06276 4/20 0.42
GRIN1 Q05586 4/20 0.42
GRIN2A Q12879 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
PKM P14618 1/20 0.41
RAB9A P51151 1/20 0.41
NQO2 P16083 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP1A2 P05177 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14690472 0.87 LMNA (0.56) LMNAKDM4EMAPTALDH1A1CYP3A4
SCHEMBL17734598 0.85 LMNA (0.54) LMNAKDM4EMAPTALDH1A1CYP3A4
SCHEMBL30572382 0.84 LMNA (1.00) LMNAKDM4EMAPTALDH1A1ELANE
SCHEMBL4768081 0.84 LMNA (1.00) LMNAKDM4EMAPTALDH1A1ELANE
SCHEMBL2538787 0.84 KDM4E (0.66) LMNAKDM4EMAPTALDH1A1CYP3A4
SCHEMBL32474876 0.84 LMNA (0.52) LMNAKDM4EMAPTALDH1A1CYP3A4
SCHEMBL7695488 0.84 LMNA (0.52) LMNAKDM4EMAPTALDH1A1CYP3A4
Hydrochloric Acid SCHEMBL9494656 0.82 LMNA (0.96) LMNAKDM4EMAPTALDH1A1ELANE
SCHEMBL9494320 0.82 LMNA (0.64) LMNAKDM4EMAPTALDH1A1CYP3A4
SCHEMBL19689622 0.81 LMNA (0.68) LMNAKDM4EMAPTALDH1A1ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118027026-A Pyrido six-membered ring compounds and application thereof 南京宁丹新药技术有限公司 2024-05-14 CN disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
CN-116964050-A Compounds useful as T cell activators 戈萨默生物服务公司 2023-10-27 CN disclosed
EP-4262986-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS Gossamer Bio Services, Inc. (US) 2023-10-25 EP disclosed
US-20230271954-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES INC (US) 2023-08-31 US disclosed
US-20230271954-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES INC (US) 2023-08-31 US disclosed
US-20230271954-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES INC (US) 2023-08-31 US disclosed
US-RE49481-E1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease HOFFMANN-LA ROCHE INC. (US) 2023-04-04 US disclosed
WO-2022133083-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2022-06-23 WO disclosed
WO-2022133083-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2022-06-23 WO disclosed
WO-2008024423-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS XTL BIOPHARMACEUTICALS LTD. (US) 2008-02-28 WO disclosed
WO-2007087250-A2 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2007-08-02 WO disclosed
US-20070060595-A1 Novel fused heterocyclic compound and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-03-15 US disclosed
EP-1671962-A1 NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-21 EP disclosed
WO-2002026713-A1 ANTIPARASITIC COMPOUNDS KING'S COLLEGE LONDON (GB) 2002-04-04 WO disclosed
US-6320051-B1 AMINO(NH) OR OXYGEN(O) SUBSTITUTED, ENZYME INHIBITORS OF STAPHLOCCOCUS AUREUS METHIONYL T-RNA SYNTHETASE (MRS); ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2001-11-20 US disclosed
EP-1084110-A1 QUINOLONES USED AS MRS INHIBITORS AND BACTERICIDES SMITHKLINE BEECHAM PLC (GB) 2001-03-21 EP disclosed
WO-1999055677-A1 QUINOLONES USED AS MRS INHIBITORS AND BACTERICIDES SMITHKLINE BEECHAM PLC (GB) 1999-11-04 WO disclosed
US-5112837-A Inhibitors of thymidylate synthetase enzyme IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-05-12 US disclosed
EP-0318225-A2 6-Aryl aminomethyl quinoline derivatives and their use as anti-tumour agents IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271954-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG LMNA 1800/4885KDM4E 3666/4885MAPT 3016/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS LMNA 1681/4885KDM4E 4338/4885MAPT 3235/4885
US-20070060595-A1 Novel fused heterocyclic compound and use thereof JUN, CHUK, RELA LMNA 4382/4885KDM4E 1873/4885MAPT 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.